No profile data available.
Agenus Inc. (AGEN) is a healthcare company in the antiviral pharmaceuticals industry, based in Lexington, United States, with about 81 full-time employees.
It reported revenue of $114.20 million for fiscal year 2025, up 10.4% from fiscal year 2024, and net income of -$101,000. In Q2 2026 (the quarter ended June 30, 2026) revenue was $34.52 million, up 34.4% from a year before. United States was its largest region in fiscal year 2025, with 99% of revenue. Its market capitalization was $346.39 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Agenus reported $114.20 million in revenue for fiscal year 2025, up 10.4% from $103.46 million in fiscal year 2024. In Q2 2026 revenue was $34.52 million.
United States: 99% of revenue by region in fiscal year 2025, followed by Rest of World (1%).
$346.39 million as of October 9, 2026.
Listed companies of a similar size in the same industry (antiviral pharmaceuticals) include Assembly Biosciences, Inc. (ASMB), Atea Pharmaceuticals, Inc. (AVIR), Arcturus Therapeutics Holdings Inc. (ARCT), SAB Biotherapeutics, Inc. (SABS).